Literature DB >> 27806250

Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette.

Amélie Marsot1, Christine Audebert, Laurence Attolini, Bruno Lacarelle, Joelle Micallef, Olivier Blin.   

Abstract

PURPOSE: A randomized cross-over, double blind placebo controlled study of smoked cannabis was carried out on occasional cannabis smokers. The objective of this research was to describe the pharmacokinetic parameters of THC and its metabolites in plasma, oral fluid and urine, from samples obtained simultaneously to provide estimations of THC and metabolites concentrations after smoking a cannabis cigarette.
METHODS: Blood, oral fluid and urine samples were collected until up to 72 h after smoking the cannabis cigarette (4% of delta-9-tetrathydrocannabinol (THC)). THC, 11-OH-THC and THC-COOH were analyzed by gas-chromatography-mass spectrometry. Pharmacokinetic parameters were estimated from these data.
RESULTS: Eighteen male healthy adults participated in the study. In total, 560 plasma, 288 oral fluid and 448 urine samples were quantified for cannabinoids. Plasma, oral fluid and urine pharmacokinetic parameters were calculated. A wide range of median THC Cmax (1.6-160.0 µg/L and 55.4-123120.0 µg/L in plasma and oral fluid, respectively), 11-OH-THC Cmax (0-11.1 µg/L in plasma) and THC-COOH Cmax (1.0-56.3 µg/L in plasma) was observed. When expressed as a percentage of the total available THC dose, and corrected for molar equivalents, mean percentage of total THC dose excreted was 1.9 +/-2.5 % with range of 0.2-7.5%. This high inter-individual variability was also observed on other calculated pharmacokinetic parameters.
CONCLUSION: Prediction of plasma THC concentration from THC oral fluid concentration or from THC-COOH urinary concentrations is not feasible due to the large variations observed. The results from this study support the assumption that a positive oral fluid THC result or a positive urine fluid result are indicative of a recent cannabis exposure. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27806250     DOI: 10.18433/J3F31D

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  7 in total

Review 1.  Cannabis use during pregnancy: Pharmacokinetics and effects on child development.

Authors:  Kimberly S Grant; Rebekah Petroff; Nina Isoherranen; Nephi Stella; Thomas M Burbacher
Journal:  Pharmacol Ther       Date:  2017-08-25       Impact factor: 12.310

2.  Using Sesame Seed Oil to Preserve and Preconcentrate Cannabinoids for Paper Spray Mass Spectrometry.

Authors:  Brandon Bills; Nicholas Manicke
Journal:  J Am Soc Mass Spectrom       Date:  2020-01-27       Impact factor: 3.109

3.  Delta-9-tetrahydrocannabinol intoxication is associated with increased prefrontal activation as assessed with functional near-infrared spectroscopy: A report of a potential biomarker of intoxication.

Authors:  Jodi M Gilman; Meryem A Yücel; Gladys N Pachas; Kevin Potter; Nina Levar; Hannah Broos; Eve M Manghis; Randi M Schuster; A Eden Evins
Journal:  Neuroimage       Date:  2019-05-07       Impact factor: 6.556

4.  Determination of Cannabinoid Vapor Pressures to Aid in Vapor Phase Detection of Intoxication.

Authors:  Tara M Lovestead; Thomas J Bruno
Journal:  Forensic Chem       Date:  2017-06-27

5.  A comprehensive breath test that confirms recent use of inhaled cannabis within the impairment window.

Authors:  Michael W DeGregorio; Gregory T Wurz; Edward Montoya; Chiao-Jung Kao
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

Review 6.  Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding.

Authors:  Anaëlle Monfort; Ema Ferreira; Grégoire Leclair; Gregory Anton Lodygensky
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

7.  US Epidemiology of Cannabis Use and Associated Problems.

Authors:  Deborah S Hasin
Journal:  Neuropsychopharmacology       Date:  2017-08-30       Impact factor: 7.853

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.